Ahmad A Altarifi1, Bethany David2, Karan H Muchhala2, Bruce E Blough3, Hamid Akbarali2, S Stevens Negus2. 1. 1 Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. 2. 2 Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA. 3. 3 Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC, USA.
Abstract
RATIONALE: TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9 R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus β-arrestin signaling pathways coupled to MORs. Prevailing evidence suggests that TRV130 and other G-protein-biased MOR agonists may produce therapeutic analgesic effects with reduced adverse effects compared to existing MOR agonists. OBJECTIVES: This study compared the effects of acute and repeated TRV130 administration on measures of antinociception, gastrointestinal function, and abuse liability in rodents. We hypothesized that TRV130 would produce robust and sustained antinociception and abuse-related effects during repeated treatment, but that tolerance would develop to gastrointestinal inhibition. METHODS: Antinociception was assessed using a warm-water tail-withdrawal procedure in mice. Gastrointestinal function was assessed in mice using an in vivo measure of fecal output and in vitro assays of colonic propulsion and of colon and ileum circular muscle contraction. Abuse liability was assessed in rats using an intracranial self-stimulation (ICSS) procedure. (+)-TRV130 was administered with acute and repeated dosing regimens, and (-)-TRV130 was also examined in the ICSS procedure to assess stereoselectivity. RESULTS: Acute (+)-TRV130 treatment produced robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects. Repeated (+)-TRV130 treatment failed to produce tolerance to antinociception or gastrointestinal inhibition, and abuse-related effects were enhanced by repeated treatment. Effects of acute and repeated (+)-TRV130 in these procedures resemble effects of morphine, with the exception that TRV130 antinociception was more resistant to tolerance. (-)-TRV130 was inactive. CONCLUSIONS: These results suggest that TRV130 retains undesirable constipating and abuse-related effects during repeated treatment despite its bias for G-protein signaling.
RATIONALE: TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9 R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus β-arrestin signaling pathways coupled to MORs. Prevailing evidence suggests that TRV130 and other G-protein-biased MOR agonists may produce therapeutic analgesic effects with reduced adverse effects compared to existing MOR agonists. OBJECTIVES: This study compared the effects of acute and repeated TRV130 administration on measures of antinociception, gastrointestinal function, and abuse liability in rodents. We hypothesized that TRV130 would produce robust and sustained antinociception and abuse-related effects during repeated treatment, but that tolerance would develop to gastrointestinal inhibition. METHODS: Antinociception was assessed using a warm-water tail-withdrawal procedure in mice. Gastrointestinal function was assessed in mice using an in vivo measure of fecal output and in vitro assays of colonic propulsion and of colon and ileum circular muscle contraction. Abuse liability was assessed in rats using an intracranial self-stimulation (ICSS) procedure. (+)-TRV130 was administered with acute and repeated dosing regimens, and (-)-TRV130 was also examined in the ICSS procedure to assess stereoselectivity. RESULTS: Acute (+)-TRV130 treatment produced robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects. Repeated (+)-TRV130 treatment failed to produce tolerance to antinociception or gastrointestinal inhibition, and abuse-related effects were enhanced by repeated treatment. Effects of acute and repeated (+)-TRV130 in these procedures resemble effects of morphine, with the exception that TRV130 antinociception was more resistant to tolerance. (-)-TRV130 was inactive. CONCLUSIONS: These results suggest that TRV130 retains undesirable constipating and abuse-related effects during repeated treatment despite its bias for G-protein signaling.
Authors: Minho Kang; Hercules T Maguma; Tricia H Smith; Gracious R Ross; William L Dewey; Hamid I Akbarali Journal: J Pharmacol Exp Ther Date: 2011-11-30 Impact factor: 4.030
Authors: Aashish Manglik; Henry Lin; Dipendra K Aryal; John D McCorvy; Daniela Dengler; Gregory Corder; Anat Levit; Ralf C Kling; Viachaslau Bernat; Harald Hübner; Xi-Ping Huang; Maria F Sassano; Patrick M Giguère; Stefan Löber; Grégory Scherrer; Brian K Kobilka; Peter Gmeiner; Bryan L Roth; Brian K Shoichet Journal: Nature Date: 2016-08-17 Impact factor: 49.962
Authors: Ahmad A Altarifi; Yunyun Yuan; Yan Zhang; Dana E Selley; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2014-09-03 Impact factor: 4.530
Authors: Tony L Yaksh; Kelly A Eddinger; Shinichi Kokubu; Zhenping Wang; Anna DiNardo; Roshni Ramachandran; Yuelian Zhu; Yajun He; Fieke Weren; Daphne Quang; Shelle A Malkmus; Katherine Lansu; Wesley K Kroeze; Brian Eliceiri; Joanne J Steinauer; Peter W Schiller; Peter Gmeiner; Linda M Page; Keith R Hildebrand Journal: Anesthesiology Date: 2019-07 Impact factor: 7.892
Authors: Lucja Kudla; Ryszard Bugno; Urszula Skupio; Lucja Wiktorowska; Wojciech Solecki; Adam Wojtas; Krystyna Golembiowska; Ferenc Zádor; Sándor Benyhe; Szymon Buda; Wioletta Makuch; Barbara Przewlocka; Andrzej J Bojarski; Ryszard Przewlocki Journal: Br J Pharmacol Date: 2019-12-08 Impact factor: 8.739
Authors: Ning-Sheng Cai; César Quiroz; Jordi Bonaventura; Alessandro Bonifazi; Thomas O Cole; Julia Purks; Amy S Billing; Ebonie Massey; Michael Wagner; Eric D Wish; Xavier Guitart; William Rea; Sherry Lam; Estefanía Moreno; Verònica Casadó-Anguera; Aaron D Greenblatt; Arthur E Jacobson; Kenner C Rice; Vicent Casadó; Amy H Newman; John W Winkelman; Michael Michaelides; Eric Weintraub; Nora D Volkow; Annabelle M Belcher; Sergi Ferré Journal: J Clin Invest Date: 2019-03-26 Impact factor: 14.808
Authors: Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko Journal: Sci Transl Med Date: 2018-08-29 Impact factor: 17.956
Authors: C Austin Zamarripa; Shelley R Edwards; Hina N Qureshi; John N Yi; Bruce E Blough; Kevin B Freeman Journal: Drug Alcohol Depend Date: 2018-09-18 Impact factor: 4.492